BioTuesdays

Category - Developments

BIOSIGHT

BioSight completes Phase 1/2a leukemia trial

Closely-held BioSight has completed patient treatment in its ongoing Phase 1/2a clinical study of Astarabine in acute leukemia patients and expects to report final results in coming months. The Phase 1/2a trial is an...

FDA rejects TransEnterix SurgiBot submission

The FDA has advised TransEnterix (NYSE MKT:TRXC) that its SurgiBot System does not meet the criteria for substantial equivalence based on the data and information submitted by the company in its 510(k) submission.“The...

Titan Pharma presents Phase 3 Probuphine data

Titan Pharmaceuticals (NASDAQ:TTNP) has presented data from the last Phase 3 study of Probuphine, a six month subdermal buprenorphine implant for the long-term maintenance treatment of opioid addiction, at a poster...

Avivagen

Avivagen plans JV to sell OxC-beta in China

Avivagen (TSX-V:VIV) plans to collaborate with the Jintai group of companies for a joint venture to commercialize OxC-beta Livestock in China. The companies plan to create a Sino-Canadian joint venture company based in...

Soricimed

Soricimed to present four posters at AACR

Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20. The presentations are based on...

oramed

USPTO extends Oramed patent term

The U.S. Patent and Trademark Office has issued a patent term adjustment (PTA) extending the patent term by 18 months for Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent titled, “Methods and Compositions for Oral...

oramed

Oramed completes Phase 2b oral insulin study

Oramed Pharmaceuticals (NASDAQ:ORMP) said that all follow-up visits in its Phase 2b study of its oral insulin capsule, ORMD-0801, have been completed. The double-blind, randomized Phase 2b study of 180 patients with...

Subscribe

Sign up to our weekly BioTuesdays newsletter.